Discovery and validation of a urinary extracellular vesicleprotein signature for the diagnosis of renal allograftfibrosis
Quick Facts
- Publication title: Discovery and validation of a urinary extracellular vesicleprotein signature for the diagnosis of renal allograftfibrosis
- Journal: Interdisciplinary Medicine
- Year: 2026
- DOI: 10.1002/inmd.70108
Research overview
Our study is the first to report the suEV protein biomarkers for the diagnosis of allograft fibrosis, offering a non‐invasive alternative to renal biopsy and enabling improved risk stratification for transplant patients, which aids in better management of transplant recipients to improve long‐term allograft survival. Through unbiased proteomic and in‐depth bioinformatic analyses, we delineated an extensive protein landscape of suEVs and identified sorting nexin 3 (SNX3), vacuolar protein sorting‐associated protein 4B (VPS4B) and smoothened (SMO) proteins as potential biomarkers for accurate and consistent diagnosis of fibrosis.
Echo Biotech Role
Echo Biotech contributed EV characterization.
Related platforms: Exoomics®
Related services and capabilities: EV Basic Characterization (TEM/NTA/WB)
References
Original publication: Discovery and validation of a urinary extracellular vesicleprotein signature for the diagnosis of renal allograftfibrosis Interdisciplinary Medicine. 2026. DOI: 10.1002/inmd.70108.